Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cixutumumab with Cisplatin and Pemetrexed in Advanced Nonsquamous NSCLC
NCT01232452Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2011
- Primary completion
- Jan 2013
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 2 trial of cixutumumab in non-small cell lung carcinoma (NSCLC), sponsored by Eli Lilly and Company. Started Apr 2011; status: completed.
02
Drugs
cixutumumab
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT01232452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01232452.